| Neuropsychopharmacology | |
| Cover: | NeuropsychopharmacologyCover.png |
| Editor: | Tony P. George, Lisa M. Monteggia |
| Discipline: | Neuropsychopharmacology |
| Abbreviation: | Neuropsychopharmacology |
| Publisher: | Nature Portfolio |
| Frequency: | Monthly |
| History: | 1987-present |
| Openaccess: | Hybrid
|
| Impact: | 7.6 |
| Impact-Year: | 2022 |
| Website: | https://www.nature.com/npp/ |
| Link1: | https://www.nature.com/npp/current-issue |
| Link1-Name: | Online access |
| Link2: | https://www.nature.com/npp/volumes |
| Link2-Name: | Online archive |
| Oclc: | 815994337 |
| Coden: | NEROEW |
| Issn: | 0893-133X |
| Eissn: | 1740-634X |
Neuropsychopharmacology is a monthly peer-reviewed scientific journal published by Nature Portfolio. It was established in 1987 and is an official publication of the American College of Neuropsychopharmacology. The journal covers all aspects of neuropsychopharmacology, including clinical and basic science research into the brain and behavior, the properties of agents acting within the central nervous system, and drug targeting and development. In addition to primary articles and reviews, the journal publishes Brainpod, a podcast highlighting content published in the journal and featuring interviews with the authorship team.[1]
Over the years, there have been ten editors-in-chief ("principal editors"), including J. Christian Gillin (1987-1993), Ronald D. Ciaranello (1994), Herbert Y. Meltzer (1994-1998), Hans C. Fibiger (1995-1998), Robert H. Lenox (1999-2001), Charles B. Nemeroff (2002-2006), and James H. Meador-Woodruff (2007-2012) and William A. Carlezon, Jr. (2013-2022).[2] Since 2023, Tony P. George (University of Toronto) and Lisa M. Monteggia (Vanderbilt University) have been co-editors.
The journal is abstracted and indexed in:According to the Journal Citation Reports, the journal has a 2022 impact factor of 7.6.[3]